Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Mallinckrodt
Express Scripts
Dow
Moodys
AstraZeneca

Last Updated: December 1, 2021

DrugPatentWatch Database Preview

Details for Patent: 7,713,947


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 7,713,947 protect, and when does it expire?

Patent 7,713,947 protects MAVENCLAD and is included in one NDA.

This patent has fifty-nine patent family members in twenty-nine countries.

Summary for Patent: 7,713,947
Title:Cladribine regimen for treating multiple sclerosis
Abstract: The present invention is related to the use of Cladribine for the preparation of a pharmaceutical formulation for the treatment of multiple sclerosis, especially relapsing-remitting multiple sclerosis or early secondary progressive multiple sclerosis, wherein the preparation is to be orally administered and wherein re-treatments are possible.
Inventor(s): De Luca; Giampiero (Conches/Geneva, CH), Ythier; Arnaud (Collex-Bossy, CH), Munafo; Alain (Tartegnin, CH), Lopez-Bresnahan; Maria (Lincoln, MA)
Assignee: Merck Serono S.A. (Coinsins, Vaud, CH)
Application Number:11/722,018
Patent Claim Types:
see list of patent claims
Use; Formulation; Delivery; Dosage form;

Drugs Protected by US Patent 7,713,947

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Emd Serono Inc MAVENCLAD cladribine TABLET;ORAL 022561-001 Mar 29, 2019 RX Yes Yes ⤷  Try it Free ⤷  Try it Free TREATING MS WITH ORAL CLADRIBINE ACC. TO THE STEPS (I) INDUCTION PERIOD WITH ABOUT 1.7 MG/KG-3.5 MG/KG CLADRIBINE; (II) CLADRIBINE-FREE PERIOD OF ABOUT 8-10 MONTHS; (III) MAINTENANCE PERIOD WITH ABOUT 1.7 MG/KG CLADRIBINE; (IV) CLADRIBINE-FREE PERIOD ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,713,947

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
04106909Dec 22, 2004
PCT Information
PCT FiledDecember 20, 2005PCT Application Number:PCT/EP2005/056954
PCT Publication Date:June 29, 2006PCT Publication Number: WO2006/067141

International Family Members for US Patent 7,713,947

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 052830 ⤷  Try it Free
Argentina 106246 ⤷  Try it Free
Austria 547106 ⤷  Try it Free
Australia 2005318190 ⤷  Try it Free
Australia 2011200768 ⤷  Try it Free
Brazil PI0517132 ⤷  Try it Free
Canada 2588966 ⤷  Try it Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Medtronic
Harvard Business School
Baxter
McKinsey
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.